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Special Feature

The Clinicians' Guide to Creutzfeldt-Jakob Disease
Thomas H. Swanson, MD*

Creutzfeldt-Jakob disease, a transmissible, rapidly progressive dementia of unknown etiology, mimics
Alzheimer's disease, presents in middle life, and affects many central nervous system structures. The
disease progresses in three distinct stages, culminating in death. Its occurrence is sporadic and its
distribution worldwide. Pathological changes are varied, but spongy degeneration ofthe neuropil is
classic. Research on scrapie, the anirrml model of Creutzfeldt-Jakob disease, has demonstrated that
this unconventional, slow disease is transmitted via a small (less than 50,000 mW) particle, which is
composed principally of protein. How this infectious particle, variably rmmed prion, virino, or slow
virus, invokes disease or is transmitted is unclear The agent does not evoke a host immune response,
nor does it appear to contain nucleic acid. No treatment has proven successful, although amantadine
has been partially effective in some cases. Decreased brain concentrations of dopamine and
norepinephrine are associated pharmacological abnormalities. (Henry Ford Hosp Med J
1987:35:76-83)

reutzfeldt-Jakob disease (CJD), a sporadic, dementing,
transmissible illness, is tmly "one in a million," not only in
its incidence but in its novel etiology as well. In the past, clinicians have had little exposure to this disease, but with recent recognition of human growth hormone-related CJD and advances
in understanding the etiology of scrapie, a related animal disease, CJD has gained notoriety. While many excellent reviews
discuss various aspects of CJD, a concise clinical guide to the
affliction is conspicuously lacking in the literature. It is my intention to provide a review of reasonable brevity, encompassing
the areas of CJD research of most interest and practical value to
the clinician. For this reason, every available paper in the literature is not reviewed. Instead, I have reviewed works that represent current, state-of-the-art developments important in our
understanding this disease and those that detail historical developments, which serve to highlight the exciting evolution of enlightenment in this area.
In 1920 Creutzfeldt described a progressive neurological disorder with dementia so similar to Alzheimer's disease that at one
point it was named Alzheimer's type II disease (1,2). One year
later, Jakob described four patients with similar signs and symptoms (3). Although thesefirstcases were probably not tme cases
of CJD as we know it, Creutzfeldt and Jakob are still honored by
the eponymic designation (4). Since then, hundreds of reports of
the same disorder have appeared in the literature, with names
such as spastic pseudosclerosis, corticopallidospinal degeneration, corticostriatalspinal degeneration, subacute spongiform
encephalopathy, and Heidenhain's disease (5). The confusing
nomenclature of this disease reflects our misunderstanding of
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what may be the most exciting group of diseases of the decade.
CJD is grouped with other slow viral diseases of the nervous system which are caused by an unconventional infectious agent and
cause progressive, noninflammatory, spongiform encephalopathies in animals and man. The characteristics that classify these
diseases as "slow," a term coined by Sigurdsson in 1954 (6),
are: 1) a long incubation period between exposure to the infectious agent and manifestations of the disease, usually months to
years; 2) a progressive clinical course typically fatal in weeks to
months; and 3) localization of the disease to one organ system
(7).
Three other diseases are coclassified as unconventional, slow
diseases: I) scrapie, affecting sheep and goats; 2) kum, affecting
humans (8); and 3) transmissible mink encephalopathy. Much of
what is known about the CJD infectious agent has been gleaned
from research on these other infectious agents, particularly
scrapie. Therefore, references will be made to the scrapie agent
periodically throughout this paper

Diagnosis
CJD presents late in middle life as a progressive central nervous system disease (9). Often the disease presents insidiously
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with vague symptoms of confusion, depression, insomnia,
peculiar sensations, and visual complaints (9). A progressive
dementia develops within weeks to months, with clinical signs
and symptoms of cerebellar, basal ganglial, focal motor, pyramidal, and lower motor neuron involvement (9,10). Although
myoclonus is a common late occunence, it may appear at any
stage ofthe disease (9). In addition, seizures develop occasionally (9), Patients then progress to an akinetic state and typically
die within one year (9,10). Sleep apnea has been reported in
several cases, but is not a consistent finding (11). Electroencephalographic changes initially include attenuation of background activity and appearance of nonspecific dysrhythmic
changes (9,10,12,13), This activity progressively evolves to generalized slow-wave activity associated with variable degrees of
bilaterally diffuse synchronous discharges (9,10,12,13). Although some authors disagree, periodic lateralized epileptiform
discharges (PLEDs) may be an eariy electroencephalographic
manifestation (14). Brain stem auditory- and visual-evoked as
well as somatosensory-evoked potentials are all normal (15).
Spinal fiuid in CJD is reported to be normal by most authors
(9,10,12,13), although some patients have shown a mild increase
in cell count and/or protein (9), and increased IgG protein with
oligoclonal bands has been reported in both the "typical" and
"ataxic" forms (15,16). Computerized tomographic scanning
and magnetic resonance imaging reveal no abnormalities except
mild cerebral atrophy in some cases (17).
Bernoulli et al (18) reviewed the early clinical features of CJD
in 100 cases and suggested that three stages of the disease exist
as originally proposed by Jansen and Monrad-Krohn (19). During stage I the patient becomes aware of some physical or mental
disorder, with minor sensorimotor or behavioral changes, which
are initially insufficient to interfere with daily life. Stage II
heralds signs of definite neurologic dysfunction with some
alteration in the patient's day-to-day activities. Stage III is characterized by incapacitating dementia, usually with severe
myoclonus.
Included in the differential diagnosis of CJD are Alzheimer's
disease. Pick's disease, normal pressure hydrocephalus,
Parkinson's disease, Huntington's disease, amyotrophic lateral
sclerosis, progressive supranuclear palsy, multiple sclerosis,
intracranial mass lesions, cerebrovascular disease, a variety
of metabolic or toxic encephalopathies, Gerstmann-Straussler
syndrome, Schilder's disease, and striatonigral degeneration
(18,20).
Various subtypes of CJD have been described including
"ataxic" (15,21,22) and "amyotrophic" (23) forms. In the
ataxic form, cerebellar involvement represents the major pathological and clinicalfindings.In this subgroup of CJD, cerebellar
biopsy has been advocated as the best diagnostic procedure (15).
Salazar et al (23) studied the so-called amyotrophic forms of
CJD, which lack the spongiform changes of typical CJD and
affect primarily lower motor neurons of the spinal cord, brain
stem, and substantia nigra. They found them not to be transmissible, which was conoborated by Masters et al (24), Salazar
et al (23) concluded that many such syndromes of dementia and
early lower motor neuron signs are clinically and pathologically
different from CJD, Dividing CJD into ataxic and amyotrophic
forms may thus be enoneous.
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In view ofthe similarities of Alzheimer's disease to CJD,
many authors have sought a commonality between the two diseases (4,24-27). Both diseases are presenile dementias with
equal sex preponderance. Age at onset and familial tendencies
are common to both diseases, although the duration of
Alzheimer's disease is much longer than that of CJD (eight years
versus eight months). Brown et al (27) reviewed the clinical,
pathologic, genetic, and biologic similarities between these two
diseases, which are numerous (27). However, consistent transmission of Alzheimer's disease to animals, considered to be of
diagnostic significance in CJD, is not yet possible (27). Although Tateishi et al (28) found similar staining characteristics between Alzheimer's disease plaques and CJD amyloid,
Pmsiner (29) has found immunohistochemical evidence to suggest that the amyloid-type plaques of Alzheimer's disease are
different from those of other transmissible dementias. Based on
these observations, Alzheimer's disease and CJD don't appear
to have comon etiologies (ie, prion or slow viral); however,
search for a possible link between the two diseases continues,
Pmsiner (30) suggests looking for clues to link slow, unconventional viral diseases, or prion-induced diseases, to a number
of neurological diseases including Parkinson's disease,
amyotrophic lateral sclerosis, and Huntington's disease, as
well as diabetes mellitus, rheumatoid arthritis, and lupus
erythematosus.

Etiology
Subsequent to the first description of CJD, numerous worldwide reports substantiated its sporadic distribution (31). Early
attempts to identify its etiology were unsuccessful, although
several hypotheses were suggested. In 1936 Josephy (32) implicated a vitamin deficiency state similar to pellagra, due to eariy
reported cases exhibiting features of dermatitis and diarrhea.
Zimmerman (33) in 1928 and then Foley and Brown (34) in 1957
suggested that the neuronal changes seen in CJD were secondary to a primary astrocytic disturbance. In 1960 Nevin et al (35)
felt that "some form of vascular dysfunction without gross
stmctural changes in blood vessels" was responsible for the disease, as evidenced by the gross postmortem similarities between
CJD brain tissue and chronic anoxic encephalopathic brain
tissue. In 1962 Siedler and Malamud (5) suggested that an endogenously determined metabolic or biochemical defect may be
the cause of, or at least contribute to, the degeneration. In support ofthis idea was Korey et al (36), who found areas of generalized lipid depletion, especially in ganglioside fractions, in
formalin-fixed, CJD brains.
In 1962 Pany (37) published a review on scrapie, concluding
that this disease was infective but that susceptibility to infection
was genetically passed in an autosomal recessive pattern. He
also felt that scrapie resulted via a dual mechanism of gene and
provims, which was gene determined but which lacked certain
properties of a natural virus. Pany seems to have predicted the
nature of scrapie in an extraordinarily accurate manner. His
ideas appear, at least in light of cunent evidence, to best explain
evolving data. Each of the other, aforementioned hypotheses has
been shown to be partially or totally inconect, although many
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components of these early ideas may still fit the framework of
cunent thought.
The definitive work on the subject of CJD etiology was published in 1968 (39), Two years after Gajdusek et al (38) showed
that kuru, another unconventional, slow disease, was transmissible to chimpanzees, Gibbs et al (39) revealed that CJD was
also transmissible to chimpanzees. Subsequently, Manuelidis et
al (40-43) successfully passed human CJD to guinea pigs, hamsters, and mice, thus providing a good laboratory animal model
for studying CJD. The demonstration of a transmissible dementia has opened new avenues in neurological research. In fact, the
concept of transmissible dementia has had such an impact on our
understanding of neurologic disease that Gajdusek was awarded
the Nobel Prize for his work with kum.
Some authors have identified spiroplasma, a helical, motile
mycoplasma, in CJD brain biopsies (44-46). Since this organism is often closely associated with vims particles. Gray et al
(45) postulated that the CJD infectious particle may represent
fragments of spiroplasma. However, Leach and Matthews (47)
failed to detect this organism by cultivation and serological testing in CJD brain tissue, nor could Manuelidis (4) detect the
organism by electron microscopy.
The aforementioned data argue for an infectious nature of
CJD, and much work is cunently ongoing to identify the infectious particle. However, by no means is the etiology firmly
established as infectious. In 1983 Traub (10) put forth a
provocative hypothesis that CJD may arise de novo by DNA mutation. A unique view of the accumulated data on CJD supports
Traub's ideas, which, as our knowledge of oncogenes and viralinduced changes in nucleic acid expands, may prove to be compatible with the more widely held view that CJD is slow viral or
prion induced (10).
Despite advances in the understanding of CJD in recent years,
its etiology remains only partially understood. As is usually tme
with sound scientific experimentation, research in this area
raises more questions than it answers. Our expanding understanding of scrapie and CJD has prompted us to reexamine the
boundaries that separate the so-called genetically passed diseases from infectious diseases.

Biochemistry
Injection of certain protein-enriched fractions isolated from
CJD-infected brains into the brains of nonnal animals results in
CJD infection in the animal. Thus, contained in the fraction is
all the information needed for infection. The mechanism by
which these protein fractions interact with the uninfected host to
produce disease remains unknown. In addition, other problems
obscure our understanding of this agent: 1) it has not been unequivocally visualized by electron microscopy, 2) a nucleic acid
content or other macromolecular stmctural components have not
been completely identified, and 3) the particle does not elicit a
humoral or cell-mediated immune response (48).
While the etiology of CJD is generally thought to involve
some sort of infectious particle, characterization of that particle
has been fraught with difficulty. Much of our cunent understanding of CJD and CJD-related agents is extrapolated from
data utilizing the more easily studied scrapie agent. In a land-
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mark article in Science, Pmsiner (30) reviewed some ofthe biochemical properties of the scrapie agent, coining the term
"prion," which stands for proteinaceous infectious (particle).
The agent is ineversibly inactivated by alkali, which denatures
RNA, double-stranded DNA, and protein, but is resistant to nuclease digestion, ultraviolet inadiation, incubation with zinc,
photochemical inactivation with psoralens, and inactivation
with hydroxylamine (30). As these procedures tend to degrade
nucleic acid but not affect the agent, either the CJD agent contains no nucleic acid or its nucleic acid is well protected (30).
The agent, however, is sensitive to protease inactivation, indicating a necessary protein component (30). The agent is hydrophobic and occurs in various sizes, the smallest with a molecular
weight under 50,000, which is too small to contain enough nucleic acid to code for an infectious protein. Numerous hypotheses have arisen concerning the nature of the scrapie agent,
including self-replicating proteins, polysaccharides, or
nucleoproteins; membrane bound DNA; viroids; and virinos
(30,48).
One month after Pmsiner described prions in 1982, Kimberlin
(49) proposed that the agent be classified more appropriately as
a virino. Virinos lie somewhere between viroids and vimses biologically. Viroids are infectious particles of plants composed of
single-stranded, closed, circular RNA, are devoid of protein,
and replicate but are not translated. Considerable controversy
exists over how to classify the scrapie-causing agent. The following five working hypotheses were set forth by Pmsiner (30):
If the agent does indeed contain "protected" nucleic acid, it may
1) code for the prion protein, or 2) activate transcription of host
genes coding for prion proteins. Altematively, if the agent is devoid of nucleic acid, its protein may 3) activate transcription of
host genes coding for prion protein, or code for its own replication by either 4) reverse translation or 5) protein directed protein
synthesis (30). These hypotheses must be considered in light of
cunent ideas about molecular biology and genetics wherein
DNA is transcribed to RNA and then translated to protein. Reverse translation has not yet been described in biology, and is, as
has been described by many, "clear biological heresy." Johnson
(48) concisely reviewed the cunent ideas conceming the scrapie
agent, addressing the work of both Pmsiner and Kimberlin. He
elegantly captures the excitement inherent in this area of slow
viral research in his closing lines, referring to Pmsiner's prions:
"If they are regulatory proteins that activate the host genes to
synthesize themselves, they will rattle the shutters of biology; if
they are proteins capable of reverse translation or protein-directed synthesis, they will shake the foundations" (47).
Are the "shutters" starting to rattie? In 1983 McKinley et al
(50) isolated a unique protein, PrP 27-30, shown to be a major
component of the infectious scrapie particle in hamsters and
capable of polymerizing into amyloid-type rods (51). Bendheim
et al (52) succeeded in producing antisemm to PrP 27-30 and
recently described cross-reaction of this antisemm with particles causing CJD in rodents (53). In 1985 Bockman et al (54)
provided evidence for prion proteins in human brains infected
with CJD; these prion proteins cross-react with the PrP 27-30
antiserum from hamsters and are histochemically similar
to amyloid, ie, stain with Congo red and exhibit green
birefringence under polarized light. Thus, antiserum to PrP
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27-30 may be used to locate CJD prion proteins in brain tissue
and may well supplant the transmissibility criterion as discussed
previously.
Merz et al (55,56) have identified similar low molecular
weight protein isolated from synaptosomal preparations of
scrapie-infected hamster brain, as well as human CJD-infected
brain. They call this protein scrapie-associated fibrils (SAF),
which may represent either 1) a unique pathological response to
the disease, or 2) the infectious agent itself (55,56). Diringer et
al (57) further purified the SAF and conoborated the work of
Merz et al. This protein seems analogous to the prion protein
described by Pmsiner, not only in biochemical properties and
distribution but also when examined by electron microscopy,
and has in fact been found to be composed of protease resistant
glycoprotein (58).
Brain monoamine abnormalities have been found in both the
"amyotrophic" and "typical" forms of CJD (59). These abnormalities consist of reduced dopamine concentration in the caudate nucleus, putamen, and mesencephalon in the amyotrophic
form, and reduced dopamine in the putamen only in the typical
form (59,60). This information is of interest in light of the beneficial therapeutic effect of amantadine reported in several cases
of CJD (61,62). In addition to its antiviral actions, amantadine
increases brain dopamine levels, probably by releasing endogenous dopamine. Some reduction in brain norepinephrine concentration has been seen in both forms, but not to the same
degree as dopamine (59). Little change in brain serotonin concentration has been noted in either form (59).
Timperly et al (63) demonstrated a loss of oxidative and
lysosomal enzymes in neurons in one case of CJD, These workers also found loss of cytoplasmic RNA and nuclear DNA, as
well as accumulation of lipofuscin in neurons of the same case
(63). The significance of these latterfindingsis unknown, but
the former may help explain the lack of immunological or
inflammatory response common in CJD.

Neuropathology
Transmissibility of the degenerative changes constitutes the
definitive diagnostic criterion used in classifying CJD. Spongy
changes usually in the neuropil (due to progressive fusion of
swollen cellular processes) but occasionally in neurons and astrocytes, along with variable degeneration of neurons and astrocytic gliosis (both hypertrophic and hyperplastic), represent the
major pathological alterations of affected brain regions (64-67),
These changes gave rise to the term subacute spongiform encephalopathy. In addition, amyloid plaques have been a variable
finding in CJD, which is of interest considering the work of
Pmsiner et al (30,51). Masters and Richardson (64) distinguish
between the terms spongiform change and status spongiosum,
the latter designating nonspecific, end-stage gliosis typified by
inegular cavitation of the neuropil accompanied by a dense glial
meshwork. Conversely, spongiform change designates small,
round, or ovoid vacuoles within the neuropil, the result of a
more acute process (64). In their review of 24 cases of CJD
in humans. Masters and Richardson (64) found the cerebral
cortex to be most severely involved, as judged by the degree of
neuronal loss, gliosis, and spongiform change, followed by the
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dorsomedial nucleus of the thalamus, caudate, putamen, and
cerebellum. The anterior nuclear thalamic groups and ventral
lateral thalamic nucleus were affected to a lesser extent, while
the hippocampus, midbrain, pons, medulla, and spinal cord
were minimally affected (64).
Manuelidis, in his 1985 Presidential Address to the American
Association of Neuropathologists, nicely reviewed the neuropathologic changes seen in this disease, particularly with
respect to transmissibility to animal models, which has both diagnostic and research significance (4).
Arendt et al (68,69) demonstrated neuronal loss in the basal
nucleus of Meynert (a major cortical cholinergic projection center), which may help explain the dementia and cholinergic deficiency often seen in this disease. These authors found identical
pathology in the brains of patients with Alzheimer's disease
(68). Hauw et al (70), who reviewed 50 cases of CJD with cerebellar involvement, found no conelation between the presence
of clinical cerebellar signs and symptoms and prominent cerebellar changes pathologically. They concluded that a cerebellar
variant of CJD is not likely, in contrast to views held by other
authors which suggest a special cerebellar subgroup (70,71).
Meier (72) demonstrated isolated, small, dark cells near involved neurons and astrocytes, which he thought were most
likely lymphocytes. He concluded that transmission of CJD may
be mediated by blood cells bearing the infectious particle (72).
Supporting this idea is the observation that viremia in experimental CJD-infected guinea pigs occurs following leukocyte
inoculation (73,74).
The gray matter changes discussed represent the relevant
pathology in most cases of CJD, However, adherence to strict
criteria of spongiform change and neuronal destmction in diagnosis of CJD may be misleading. The disease can be present
without spongiform change and may involve extensive white
matter degeneration (75). In a study of retinal degeneration of
CJD-infected mice, Hogan et al (76) found pathological similarities between human retinal diseases, such as retinitis pigmentosum, retinitis punctata albicans, and senile macular
degeneration, and their mouse model. These authors speculate
as to possible slow viral etiologies of so-called "genetic" diseases. Roth et al (77) found vims-like particles in the optic nerve
head of a patient with CJD, which were morphologically similar
to those found in the brain. This finding supports the suggestion
of a slow viral etiology for some retinal degenerations in man.
For extensive descriptions of light microscopic as well as
scanning and transmission electron microscopicfindingsin the
CJD-infected brain, interested readers are refened to the works
of Chou et al (78), Kim and Manuelidis (66), or Manuelidis and
Manuelidis (79). Chou et al (78) found no evidence of conventional viral stmctures in affected tissues examined by both transmission and scanning electron microscopy. They found only
membrane alterations and particulate structures on intravacuolar
membranes (78). Bockman et al (54) published electron micrographs of prion amyloid-type rods, although amyloid deposition
is not a consistent finding in CJD, occurring in about only 12%
of all cases.
CJD-causing agents, whatever their constitution, represent a
hazard to neuropathologists working with diseased tissue, because of their unusual resistance to aldehydefixatives(80-82).

Clinicians' Guide to CJD—Swanson

79

Infectivity is reported to be maintained even in paraffin-embedded tissue blocks (83). Brown, Baringer, and others (80-84) recommend autoclaving tissue for one hour at a temperature of at
least I 2 r c (15 psi) as the procedure of choice for CJD inactivation; however, a one-hour exposure to 0.5% sodium hypochlorite is a good alternative. Masters et al (85) reported a
procedure for decontaminating formaldehyde fixed tissues by
autoclave, without loss of microscopic visual quality. However,
this latter procedure does destroy immunoreactivity (85).

Epidemiology
According to Masters et al (31), distribution of CJD is worldwide, having been reported on five continents. Possible clustering of cases has been reported in England, Czechoslovakia,
Hungary, and among Libyan Jews (9,31). No urban-rural
differences have been reported, and estimates of the annual incidence of CJD per 1 miflion range from 0.1 to 5, with 1 per 1 million accepted by many authors to be a reasonable estimate
(4,9,31,86). This figure also represents the prevalence rate,
because the average duration of disease is about one year (9,30).
The range of age at onset is reported to be between 35 and 65,
with a mean age of mid 50s reported by various authors (9,32).
However, patients as young as 20 years old have been described
with spontaneous CJD (87), While it is hard to ascertain the exact date of onset in CJD, the mean duration of disease is considered to be eight to 12 months, although cases of up to 13-years
duration have been reported (9), The male to female ratio of CJD
is close to one (9),
The Libyan Jewish population in Israel represents the only
obvious racial bias in CJD occunence, with a cmde rate of 51 per
1 million annually (9,88), This bias may reflect genetic susceptibility or increased exposure to an unknown risk factor (88),
Curiously, the practice of eating animal brains and sheep eyes is
popular among this population group (88).
The mode of transmission of CJD is still uncertain. Ongoing
research is working to substantiate an infectious etiology, and
transmission is thought to occur by one of three general mechanisms: 1) iatrogenic exposure, 2) occupational exposure to CJD
patients or animals, or 3) preparation or consumption of CJDinfected brain tissue or raw meat (9).
Iatrogenic causes have been confirmed in an increasing
number of CJD cases. Two patients contracted the disease following contact with intracerebral EEG electrodes contaminated
by a CJD patient (89), and one patient contracted the disease following a corneal transplant from a CJD-infected donor (90).
Nevin et al (35) found that four of eight CJD patients studied had
a history of intracranial surgery or ventriculography 16 to 24
months before onset of the disease. In a study of 60 cases of
CJD, Kondo and Kuroiwa (91) concluded that physical injuries
and operations may be a predisposing factor to the development
of the disease. However, in a case control study of 38 patients,
Bobowick et al (92) found no significant difference between
groups of patients with prior cranial or surgical histories and the
controls. Similarly, Matthews (93) reported that only two of 46
patients had a prior history of intracranial surgery. Koch et al
(94) and Gibbs et al (95) described iatrogenically-induced CJD
in young patients receiving human cadaveric growth hormone.
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Brown et al (96) commented on the "ominous possibility of a
burgeoning epidemic" of CJD due to use of human growth
hormone.
The familial form of CJD that exists is estimated to represent
12% to 14% of all cases. It is inherited in an apparently autosomal dominant manner (9,26). A female predilection is evident, but matemal and patemal lines are affected equally (26). In
a study of 37 families with the familial form of CJD, Masters et
al (26) found no direct evidence to support prenatal vertical
transmission; however, affected siblings tended to die at similar
ages, though not at the same time, which suggests vertical transmission. Despite the latterfindings,they concluded that a genetically inherited susceptibility to infection, acquired early in life,
is most probable in CJD (26).

IVeatment
Although current research activity with the scrapie agent
points away from a viral etiology, many still classify the CJD
agent as viral. Antiviral dmgs such as amantadine, acyclovir,
vidarabine, and interferon, and even various antibacterial dmgs
have thus been tried in the treatment of CJD, but with little
success. Acyclovir, a DNA vims inhibitor, was found to be ineffective in both early and late stages of the disease (97,98). Interferon has been reported to be useful in treating experimental
scrapie (99), but use in humans with CJD has proven disappointing. However, it may fail to reach sufficient concentration in
cerebrospinal fiuid, being only 'Ao of serum concentrations
(100). Thus, the efficacy of intrathecal interferon administration
should be assessed. Thiamphenicol, rifampicin, cytosine arabinoside, and isoprinosine have been tried in experimental CJD in
mice, without significant effect (101). Vidarabine suppressed
some motor symptoms in one reported case of CJD, but failed to
halt progression of the disease (102). Amantadine is the only
agent reported to have significant therapeutic effects, but only in
isolated cases (103,104). Terzano et al (103) reported a transient
improvement in wakefulness and mentation, and reduction in
EEG slow-wave activity and periodic discharges with amantadine therapy. Braham (105) felt these effects may correlate
with amantadine's ability to increase central dopamine, a biochemical rather than antiviral effect. This information makes
sense in view of the work of Nyberg et al (58), who showed a
consistent reduction in brain dopamine concentration in CJDinfected human brain. Braham (105) tried 5 g/day of levodopa
via a nasogastric tube in one CJD patient without improvement,
although this patient's brain may have been sufficiently damaged
to render it unable to convert levodopa to dopamine. In view of
this, it may be worthwhile to try other dopaminergic dmgs such
as bromocriptine or pergolide mesylate as Braham suggests
(105). Roikhel et al (106) tried the monoamine oxidase inhibitor
aminasine in a mouse model of scrapie and found no effect when
administered intraperitoneally. These workers did, however,
find a prolonged incubation period and slight decreased morbidity when aminasine was injected intracerebrally (106). Kudo
et al (107) reported the disappearance of sleep apnea, and periodic synchronous discharges on EEG, by tracheal intubation,
suggesting that both manifestations of CJD could be due to airway obstmction.
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In short, there remains no consistently efficacious therapy in
the treatment of CJD, save supportive measures. However, continued advances in our understanding of the etiology of CJD and
the biochemical nature of the disease process will, in the future,
reveal specific areas where pharmacological manipulation may
improve the lives of patients with this disease and related
afflictions.

Conclusion
A word about naming the scrapie agent is in order due to the
heated debates over the nature of its replicative machinery. Although Pmsiner has prolifically saturated the literature with the
term prion, which by virtue of its constmction emphasizes protein, all researchers are not of similar persuasion. Kimberlin, a
strong opponent of the self-replicative protein hypothesis, holds
that the particle is "vims-like." Work by Rohwer (108) serves to
substantiate the validity of Kimberlin's claim. Recent ultraviolet
inactivation data suggest that the particle could be a small vims,
although it is clear that its putative nucleic acid is "atypical,"
possibly bound to another macromolecular stmcture, ie, protein
or cell membrane (108,109). In addition, the sedimentation
behavior and buoyant density in centrifugation experiments support a nucleic acid component (108). Exclusion size in permeation chromatography is also in support of this contention (108),
as is recent data by German (110) who found a population of
small RNA molecules present only in scrapie-infected mice.
Kimberlin (111) points out that genetically stable, biologically
different strains of the scrapie disease exist, which strongly implicates the necessity of a highly efficient, precise method of
replication, deemed possible, he thinks, only with nucleic acid
(112), A recent suggestion by Hope and Kimberlin (58) is that
the infectious agent may become protected by a host-coded protein resulting in infectivity.
In support of Pmsiner (29), he does not claim that prions are
by definition devoid of nucleic acid. He upholds only that protein is necessary for infection (29). Pmsiner and coworkers (113)
have partially sequenced the PrP 27-30 protein, and Oesch et al
(114) have found evidence for a cellular gene which encodes this
protein, both in normal and infected tissue. These data argue for
scrapie or prion specific nucleic acid, but whether the nucleic
acid containing this information is contained in the infectious
particle itself or simply canied in host genes is controversial and
the subject of cunent research.
1 uphold the views of Johnson (48), in that a conservative approach be applied to naming the agent. Until its macromolecular
stmcture is conclusively revealed, definitive classification of the
agent should be withheld. Whatever its constitution, one point is
clear: the understanding of scrapie and CJD has brought us to
new frontiers in molecular biological research and has added
greatly to our understanding of central nervous system disease.
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